SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
8,70 US$
arrow_downward
-0,57%(-0,050) 1D
9. okt., 16.00.00 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Ændring | Ændring i % |
|---|
insights_autoGenererer vigtig indsigt for SGIOY...
Åbn
8,75 US$
Høj
8,79 US$
Lav
8,64 US$
Markedsværdi
2,44 bio.
Gns. vol.
163,32 t
Volumen
131,15 t
Højeste i 52 uger
12,00 US$
Laveste i 52 uger
7,65 US$
Beta
0,07
Aktier i omløb
1,78 mia.
Antal ansatte
6 t
Åbn
8,75 US$
Høj
8,79 US$
Lav
8,64 US$
Markedsværdi
2,44 bio.
Gns. vol.
163,32 t
Volumen
131,15 t
Højeste i 52 uger
12,00 US$
Laveste i 52 uger
7,65 US$
Beta
0,07
Aktier i omløb
1,78 mia.
Antal ansatte
6 t
Nyhedshistorier
Fra webkilder og nyhedspartnere
Yahoo Finance UK
·
for 1 time siden
Shionogi (TSE:4507) Weighs IntraBio Acquisition, Is The Stock A Bargain?
Simply Wall Street
·
for 16 timer siden
Shionogi (TSE:4507) Weighs IntraBio Deal, Is The Stock Undervalued?
AD HOC NEWS
·
for 3 dage siden
Shionogi agrees to buy IntraBio for USD 2.00 billion: what it means for Shionogi stock
Profil
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
Om Shionogi 2 ADR Representing 1 Ord Shs
Administrerende direktørIsao Teshirogi
Ansatte6,22 t
Grundlagt1878
Hovedsæde-
Sektor-
Websiteshionogi.com